Tissue Science Market Analysis and Reports | USA Conference Series

Market Analysis - Tissue Science 2018

USA: Regenerative medicines market by therapy (cell therapy, gene therapy, immunotherapy, tissue engineering), region - global forecast to 2021, the global regenerative medicines market size is expected to reach USD 49.41 billion by 2021,. North America contributed the largest share in the global regenerative medicines market, and was dominated largely by the USA

Europe: The global tissue engineering and regeneration market reached $17 billion in 2016. This market is expected to grow to nearly $20.8 billion in 2014 and $56.9 billion in 2019, Today, there are 640 privately held and publicly traded companies in Europe, Japan, and the U.S.

Middle East: Middle East and Africa regenerative medicines market is expected to reach USD 5.75 billion by 2021 from USD 2.03 billion in 2018, growing at a CAGR of 23.15% during the forecast period 2016-2021. Regenerative medicines repair, replace or regenerate human cells, tissues, or organs affected due to injury, disease, aging processes, congenital defects, and damage due to trauma.

Asia Pacific: Asia-Pacific regenerative medicines market is expected to reach USD 10.71 billion by 2021 from USD 3.01 billion in 2017, growing at a CAGR of 28.90% during the forecast period 2017-2021.  Cell-based products segment is estimated to account for larger share of Asia-Pacific regenerative medicines market by product in 2018.

The 12th International conference  on Tissue Engineering and Regenerative Medicine which is going to be held during November 9-10 2018 at Atlanta, Georgia, USA  will  bring together world-class personalities working on stem cells, tissue engineering and  regenerative medicine to discuss materials-related strategies for disease remediation and tissue repair. Bone tissue engineeringsoft tissuestissue imagingtissue implant, cartilage and skin defects are a special focus along with applying basic science and engineering principles from diverse areas towards solving clinically relevant genetical problems.

We welcome you to Tissue Science Conference, to be held on November 9-10 2018 at Atlanta, Georgia, USA. This conference presents information regarding cutting-edge developments in all areas of tissue engineering, stem cell research, regenerative medicine research including the biology, medicine, applications and regulations of stem cells. Topics of discussion include recent developments in pre-clinical and clinical trials of stem cell therapy, regenerative medicine and tissue engineering, cancer stem cells, immunotherapy, stem cell reprogramming, and regulatory policies regarding stem cell research.

After the success of the 6th international Conference  on Tissue Engineering and Regenerative Medicine  in 2017, it’s time for the tissue engineering and regenerative medicine industries to come together and looking forward for  the  next 10 years of commercial successes within these two sectors.

The World Conference on Regenerative Medicine  has traditionally focused on developing the commercial aspects of  tissue science research  with the addition of innovation within stem cellsregenerative medicine, notably tissue engineering.

Now the first regenerative medicine therapies have made it to market, it is important, for the success of the sector, to move forward and include new projects and innovations that are coming out of academia and university spin-outs. These will be both new developments in regenerative medicine research but also within the use of tissue engineering and stem cells for drug discovery.

Alongside the stem cells content, there is an increasing amount of demand for other forms of regenerative medicine and so the Tissue Science conference will move to include more commercial opportunities within the field of tissue engineering: markedly biological scaffolds, 3D bio printing and organ regeneration.

Through the last 5 years the Tissue Science Conference has built up a reputation for delivering high-level commercial content and bringing together the senior executives and thought-leaders within the space.